We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Vectura Group Plc | VEC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 164.80 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 164.80 |
| Top Posts |
|---|
Posted at 22/9/2021 13:12 by dave129 Hi -FYI I had the same issue of lost form - which I realised last night after reading this thread... I sent an email to the investor relations address on the vec site and this morning a new one arrived. On the way to post shortly ... |
Posted at 18/8/2021 12:26 by dontay I substantially sold out of VEC a couple of years ago and sold my very limited remaining holding last week. For anyone who would like what would be a very radicle departure from Pharma, and is looking to invest in an industry and something that's in the background of a subject that's come right to the top of the global economic agenda .... and make it explode, something that's been subjected to top quality global research and is now already starting to come to the attention of industry leaders .... you will have to enjoy the humongous amounts of DYOR that it'll take to get your head around it all and the genuine size of the opportunity that is going to happen ... have a look Bushveld Minerals (BMN) HTtps://www.bushveld |
Posted at 16/8/2021 10:32 by vecturaking ISR Immune System Regulation Holding AB (publ) (“ISR”), which develops inhalation vaccine against Covid-19, has on 6 August 2021 announced that the company has entered into a memorandum of understanding (MoU) regarding the start of a vaccine study in Bangladesh and on August 8, 2021 announced that the company has entered into a letter of intent (MoU) regarding the manufacture and distribution of ISR's vaccine in Bangladesh.ISR has noted that Bangladeshi media, including the English-language daily newspaper The Daily Star, have published information on when ISR's vaccine can be launched in Bangladesh, commercial terms on Bangladesh's acquisition of vaccine from ISR and at what rate the vaccine will be produced. Due to the information in the Bangladeshi media, ISR would like to make the following comments: ISR is currently negotiating with various parties for the delivery of the company's vaccine. Such negotiations are, for obvious reasons, confidential. If a party finances clinical studies of ISR's vaccine, it can of course affect the price the party may pay for the vaccine if it can be successfully launched. Apart from what has already been communicated in the above-mentioned press releases on 6 and 8 August 2021, ISR has not entered into any new agreements regarding the Bangladeshi market and thus there are no binding agreements on the delivery of the company's vaccine to Bangladesh. As previously communicated, ISR is pleased with the interest that the company's vaccine has received in Bangladesh. If ISR enters into an agreement for the delivery of vaccines to Bangladesh, it will be communicated to the market through customary channels. Investors in ISR should consider information about the company that is communicated by the company in customary channels. |
Posted at 11/8/2021 20:01 by slim9 hxxps://www.amrytphaPolaris .. Any thoughts ????? Cash rich - money making pharma. Cheers in advance. S |
Posted at 09/8/2021 18:46 by base7 For what it's worth I had a decent number of BTG & felt at time if takeover that we ere sold short ,despite it being a more than 10 bagger for me .I a man a recent investor in Shield & hoping for a decent outcome over the next year or two . Good luck ! |
Posted at 09/7/2021 19:18 by richtea2517 These boards are lunacy.Although in fairness there are some sensible investors on this one. Only experience will help you to take all of it without pinch of salt. |
Posted at 09/7/2021 19:10 by davr0s Maybe this account got hacked as I am sure I was told to bail out and to watch what experienced investors do... ??? |
Posted at 09/7/2021 11:09 by jimboyce Philip Morris Makes $1.24 Billion Bid for UK Respiratory Drugs Company -- UpdateSource: Dow Jones News--Philip Morris International plans to buy Vectura Group as part of expansion beyond tobacco products--Vectura board withdrew its recommendation of an earlier offer from Carlyle--Carlyle said it is considering its options By Adria Calatayud Philip Morris International Inc. plans to buy Vectura Group PLC, a U.K. pharmaceuticals business specializing in inhaled medicines, for 899.2 million pounds ($1.24 billion) in cash, bolstering its push to expand beyond tobacco and nicotine.Philip Morris International, which sells the Marlboro brand outside the U.S., on Friday said that Vectura will be the backbone of its inhaled-therapeutic business.The move from the tobacco company trumps an earlier bid for Vectura by Carlyle Group Inc., which had been recommended by the board of the U.K. company in May. Philip Morris's offer values Vectura at 150 pence a share, 10% higher than Carlyle's bid.In response, Carlyle said it is considering its options and encouraged Vectura shareholders to take no action.Shares in Vectura at 0928 GMT traded 13% higher at 153.60 pence.The offer from Philip Morris valued Vectura at GBP1.05 billion, or 169 pence a share, including a dividend of 19 pence a share the U.K. company paid in June.Philip Morris said the acquisition of Vectura is part of its evolution into a broader healthcare and wellness company. Earlier this year, it outlined plans to generate more than half of its revenue from smokeless products by 2025, up from 24% in 2020, in a bid to court ethical investors.Philip Morris said respiratory drug delivery and selfcare wellness products are key in its plans to move away from tobacco and nicotine and that Vectura's strengths can help it to tap into the fast-growing market for inhaled therapeutics."We see Vectura's combination of device, formulation and development capabilities for inhaled therapeutics as highly complementary to our existing expertise, pipeline and experience in aerosolization," Philip Morris Chief Executive Jacek Olczak said.Vectura, based in Chippenham, England, will operate as an autonomous business unit within Philip Morris with support for its current strategy, the companies said. In 2019, the company changed its strategy to focus on providing contracted drug-development services for partners.Analysts at brokerage Peel Hunt said Philip Morris's offer for Vectura reduces the likelihood of further bids from private-equity investors, as the U.K. company's plans to develop a contract development-and-manu |
Posted at 09/7/2021 10:37 by a1ord53 Yes agree with Q2U , thanks Polaris for your expertise.Please, do your own site for all post Vectura/Sky investors and we will be happy discuss new opportunities !!! |
Posted at 11/3/2021 13:37 by a1ord53 So more big guys and institutions buying Vec , so more small algo guys selling to shake out retail investors and scare them.It’s going on for years, same was with BTG - eventually bought by Boston scientific with 35% premium. Richman -CFD doesn’t pay taxes , no duty stamps - financing under 2% Otherwise all major investors know what to expect in coming results , so nobody interesting to buy yet , may be everything already discounted in share price ? |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
